Ipsen, Invida Group Sign Agreement To Commercialize Drugs In South-East Asia
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- The French firm Ipsen and Singapore's Invida have forged an exclusive distribution and promotion deal covering a number of Ipsen's oncology and endocrinology drugs in select South-East Asian countries. The agreement is expected to help expand the geographical reach of Ipsen's specialty-care portfolio in the Asia Pacific region
You may also be interested in...
Invida Charts 25% Growth Plan, Banking On Selective Partnerships For High-value Products
SINGAPORE - Big Pharma's slow shift from primary care products to specialty care products like the oncology segment has helped Invida develop robust commercial relationships with multiple partners
Invida Charts 25% Growth Plan, Banking On Selective Partnerships For High-value Products
SINGAPORE - Big Pharma's slow shift from primary care products to specialty care products like the oncology segment has helped Invida develop robust commercial relationships with multiple partners
Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access
Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies